Vol 9, No 4 (August 18, 2020): Chinese Clinical Oncology

Editorial on Ovarian Cancer1

Up-to-date in ovarian cancer
Heriberto Medina-Franco
Chinese Clinical Oncology  
2020;
9
(4)
:43
.
 (18 August 2020) 
PDF Full Text (1945) COI Form Open Access Get Permission

Review Article on Ovarian Cancer1

Role of hyperthermic intraperitoneal chemotherapy in ovarian cancer
Juan Manuel Medina-Castro, Adriana Ruiz-DeLeón
Chinese Clinical Oncology  
2020;
9
(4)
:44
.
 (18 August 2020) 
PDF Full Text (5510) COI Form Open Access Get Permission
Ovarian carcinoma: pathology review with an emphasis in their molecular characteristics
Leonardo S. Lino-Silva
Chinese Clinical Oncology  
2020;
9
(4)
:45
.
 (18 August 2020) 
PDF Full Text (7698) COI Form Open Access Get Permission
Can lymphadenectomy be omitted in advanced ovarian cancer?—a brief review
Rosa A. Salcedo-Hernández
Chinese Clinical Oncology  
2020;
9
(4)
:46
.
 (18 August 2020) 
PDF Full Text (2888) COI Form Open Access Get Permission
Epidemiology of ovarian cancer
Patricia Gaona-Luviano, Lourdes Adriana Medina-Gaona, Kassandra Magaña-Pérez
Chinese Clinical Oncology  
2020;
9
(4)
:47
.
 (18 August 2020) 
PDF Full Text (36430) COI Form Open Access Get Permission
Fertility-sparing treatment for epithelial ovarian cancer: a literature review
Milagros Pérez-Quintanilla, Sarish del Real-Ordoñez, Lenny Gallardo-Alvarado, David Cantu-de Leon
Chinese Clinical Oncology  
2020;
9
(4)
:48
.
 (18 August 2020) 
PDF Full Text (6764) COI Form Open Access Get Permission
Radiotherapy in women with epithelial ovarian cancer: historical role, current advances, and indications
Christian Haydeé Flores-Balcázar, Dulce María Urías-Arce
Chinese Clinical Oncology  
2020;
9
(4)
:49
.
 (18 August 2020) 
PDF Full Text (5386) COI Form Open Access Get Permission
Non-epithelial ovarian carcinoma: what is the optimal staging surgery?
Heriberto Medina-Franco, Luis Enrique Colonna-Márquez
Chinese Clinical Oncology  
2020;
9
(4)
:50
.
 (18 August 2020) 
PDF Full Text (3917) COI Form Open Access Get Permission
PARP inhibitors in ovarian cancer: evidence for maintenance and treatment strategies
Antonio Bahena-González, Alfredo Toledo-Leyva, Dolores Gallardo-Rincón
Chinese Clinical Oncology  
2020;
9
(4)
:51
.
 (18 August 2020) 
PDF Full Text (5689) COI Form Open Access Get Permission
Systemic therapy for non-serous ovarian carcinoma
Yanin Chávarri-Guerra, Eduardo González-Ochoa, Héctor De-la-Mora-Molina, Enrique Soto-Perez-de-Celis
Chinese Clinical Oncology  
2020;
9
(4)
:52
.
 (18 August 2020) 
PDF Full Text (6243) COI Form Open Access Get Permission
Controversies on the treatment of ovarian cancer with dose-dense chemotherapy
Alberto Súarez-Zaizar, Eduardo Cárdenas-Cárdenas, Yadira Araceli Barajas-Castro, Patricia Cortés-Esteban
Chinese Clinical Oncology  
2020;
9
(4)
:53
.
 (18 August 2020) 
PDF Full Text (3539) COI Form Open Access Get Permission

Original Article

Radical antegrade modular pancreatosplenectomy versus standard distal pancreatosplenectomy for pancreatic cancer, a dual-institutional analysis
Jonathan G. Sham, Shiwei Guo, Ding Ding, Zhuo Shao, Michael Wright, Wei Jing, Ling-Di Yin, Yijie Zhang, Michele M. Gage, Yingqi Zhou, Ammar Javed, Richard A. Burkhart, Xuyu Zhou, Matthew J. Weiss, Tianlin He, Gang Li, John L. Cameron, Xiangui Hu, Christopher L. Wolfgang, Gang Jin, Jin He
Chinese Clinical Oncology  
2020;
9
(4)
:54
.
 (18 August 2020) 
PDF Full Text (2676) Reporting Checklist Data Sharing Statement Peer Review File COI Form Open Access Get Permission
Outcomes of adjuvant whole-brain radiotherapy versus hypofractionated stereotactic radiotherapy after surgical resection of brain metastases: a propensity score-matched analysis
Audrey Keller, François Lefebvre, Damien Ricard, Georges Noël, Delphine Antoni
Chinese Clinical Oncology  
2020;
9
(4)
:55
.
 (18 August 2020) 
PDF Full Text (2258) Reporting Checklist Data Sharing Statement COI Form Open Access Get Permission

Editorial Commentary

Global burden of childhood and adolescent cancer
Emma R. Woodward, D. Gareth Evans
Chinese Clinical Oncology  
2020;
9
(4)
:56
.
 (18 August 2020) 
PDF Full Text (2693) COI Form Open Access Get Permission
Analysis of the association between adverse events and outcome in patients receiving a programmed death protein-1 or programmed death ligand-1 antibody
Marilina García-Aranda, Maximino Redondo
Chinese Clinical Oncology  
2020;
9
(4)
:57
.
 (18 August 2020) 
PDF Full Text (1394) COI Form Open Access Get Permission
REACH-2: first biomarker-based anti-angiogenic therapy in patients with advanced hepatocellular carcinoma
Hong Jae Chon, Chan Kim
Chinese Clinical Oncology  
2020;
9
(4)
:58
.
 (18 August 2020) 
PDF Full Text (1714) COI Form Open Access Get Permission
Immunotherapy in lung cancer: the chemotherapy conundrum
Laxmi Narayana R. Buddharaju, Apar Kishor Ganti
Chinese Clinical Oncology  
2020;
9
(4)
:59
.
 (18 August 2020) 
PDF Full Text (1859) COI Form Open Access Get Permission
PD-L1 expression and efficacy of pembrolizumab as monotherapy in NSCLC
Jan Trøst Jørgensen
Chinese Clinical Oncology  
2020;
9
(4)
:60
.
 (18 August 2020) 
PDF Full Text (4419) COI Form Open Access Get Permission

Disclosure:

1. The series “Ovarian Cancer” was commissioned by the editorial office, Chinese Clinical Oncology without any sponsorship or funding. Heriberto Medina-Franco served as the unpaid Guest Editor of the series.